Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer...( REDWOOD CITY Calif. Dec. 5 /- Genomic...)

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two of the studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Following are details for each embargoed session (all times are Central Standard Time):

    -- Thursday, December 11, 2008, 4 p.m. - 4:15 p.m.
       Abstract #25
       Oral presentation (General Session 2): "GRB7-dependent pathways are
       potential therapeutic targets in triple-negative breast cancer"
       Presenter: Joseph Sparano, M.D., Montefiore-Einstein Cancer Center, New
       York
       Location: Exhibit Hall D

    -- Friday, December 12, 2008, 7 a.m. - 9 a.m.
       Abstract #2066
       Poster presentation (Poster Session II: Prognosis and Response
       Predictions: Biomarkers -- Methods): "Quantitative gene expression
       analysis using Oncotype DX in ductal carcinoma in situ that is adjacent
       to invasive ductal carcinoma"
       Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer
       Center at the University of California, San Francisco
       Location: Exhibit Hall B

    -- Friday, December 12, 2008, 5 p.m. - 7 p.m.
       Abstract #3049
       Poster presentation (Poster Session III: Tumor Cell and Molecular
       Biology: Hormonal Factors and Receptors): "Associations between
       estrogen receptor (ER) Alpha expression levels and ER genotypes"
       Presenter: Daniel Hayes, M.D., University of Michigan Health Sys
'/>"/>
SOURCE  Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 
Related biology technology :

1. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
2. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Genomic Health to Present at Stephens Fall Investment Conference
6. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
7. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
8. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. /C O R R E C T I O N -- Rosetta Genomics Ltd/
10. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference